Ultragenyx : Brazil Okays Mepsevii For Treatment Of Mucopolysaccharidosis VII

(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE) said that Brazil's National Health Surveillance Agency or ANVISA has approved Mepsevii (vestronidase alfa) for the treatment of Mucopolysaccharidosis VII (MPS VII; Sly syndrome) for patients of all ages.

Mepsevii was approved by the U.S. Food and Drug Administration in November 2017 for the treatment of pediatric and adult patients with MPS VII.

In August 2018, the European Commission (EC) approved the Marketing Authorization Application (MAA) for Mepsevii under exceptional circumstances for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII.

With this decision, Mepsevii is approved in all 28 EU countries, Iceland, Liechtenstein and Norway.